Taro Pharmaceutical Industries Ltd.
TARO · NYSE
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Market Cap | $2 | $2 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 5% | 6% | -6.7% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 53% | 50.8% | 49.7% | 40.3% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 11% | 14.7% | 9.4% | 3.9% |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 9.1% | 12.9% | 5.8% | 6.3% |
| EPS Diluted | 0.4 | 0.54 | 0.23 | 0.27 |
| % Growth | -25.9% | 134.8% | -14.8% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | $0 | $0 |